Abstract
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ameliorates hyperglycemia and glucose intolerance by increasing both insulin sensitivity and insulin
Introduction

37
Glucose is a primary metabolic fuel. Blood glucose levels are maintained within a narrow range 38 through the action of insulin and other metabolic hormones (18, 34) . Insulin decreases blood glucose by 39 stimulating glucose uptake into adipose tissue and skeletal muscle and by suppressing hepatic glucose 40 production (34). Insulin resistance is the primary risk factor for type 2 diabetes (42). Additionally, 41 pancreatic β cell function is also impaired in type 2 diabetes and unable to secrete sufficient insulin to 42 compensate for insulin resistance (26). Relative insulin deficiency, due to a combination of insulin 43 resistance and impaired pancreatic β cell function, contributes to hyperglycemia and glucose intolerance 44 in type 2 diabetes. Small molecules with the capability to improve insulin sensitivity and/or β cell 45 function have a great therapeutic potential for the treatment of type 2 diabetes.
46
Growing evidence indicate that herbal constituents hold a great promise for the treatment of type 47 2 diabetes, and extracts of numerous plants have been reported to reduce blood glucose (6, 8, 17, 22, 41) .
48
In search for small compounds with an anti-diabetic property, we examined natural compounds in plant 49 extracts, focusing on inositol derivatives. Inositols consist of nine isomeric forms (myo-, scyllo-, epi-, 50 allo-, cis-, neo-, muco-, D-chiro-, L-chiro-inositol) and are synthesized from glucose-6-phosphate, a 51 glycolytic metabolite (28). Many forms of inositols and inositol derivatives are essential components of 52 membrane phospholipids in animals and humans (28, 39) . These phospholipids not only play an 53 important structural role but also mediate cell signaling (11, 39, 40) . Interestingly, insulin stimulates 54 production of inositol phosphoglycans (IPG) (21, 29, 36) . IPG is believed to act as an intracellular second 55 messenger to mediate insulin metabolic action (21, 23) . Moreover, chiro-inositol levels are decreased in 56 type 2 diabetes (3), and increased myo-inositol/chiro-inositol ratios are associated with type 2 diabetes 57 and insulin resistance in both animals and humans (20, 23) . D-chiro-inositol and 3-O-methyl-D-chiro-58 inositol (D-pinitol) have been reported to act as an insulin mimetic to improve hyperglycemia in both 59 mice and humans with type 2 diabetes (4, 7, 10, 19, 35 prefilled with either a sterile 0.9% NaCl vehicle or sequoyitol. A sequoyitol-filled pump released 83 sequoyitol at 0.5 nmol/h. For streptozotocin (STZ) treatments, C57BL/6 males (9 weeks) were 84 intraperitoneally injected with STZ (80 mg/kg body weight once a day for 2 days). The mice were fed 85 either tap water (control) or water supplemented with sequoyitol (7 mg/ml). Blood samples were 86 collected from tail veins, and blood glucose and plasma insulin were measured as described previsouly 87 (31). For GTT, mice were fasted overnight (or 6 h) and intraperitoneally injected with D-glucose (0.6-0.8 88 g/kg body weight), and blood glucose levels were monitored after glucose injection. For ITT, mice were 89 fasted for 5-6 h and intraperitoneally injected with human insulin and blood glucose levels were 90 monitored after glucose injection.
91
Immunoprecipitation and immunoblotting. Mice were fasted overnight, anesthetized, and administrated 92 with insulin via inferior vena. Livers were homogenized in a lysis buffer (50 mM Tris HCl, pH 7.5, 1.0% 93 NP-40, 150 mM NaCl, 2 mM EGTA, 1 mM Na 3 VO 4 , 100 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM PMSF, 10 94 μg/ml aprotinin, 10 μg/ml leupeptin) as described previously (32, 44 glucose levels were significantly lower in sequoyitol-treated than in vehicle-treated mice (Fig. 1C) .
139
Sequoyitol treatments also significantly reduced plasma insulin levels (by 29%) (Fig. 1C) sequoyitol also markedly improved glucose intolerance during GTT (Fig. 3B) . Surprisingly, plasma 175 insulin levels were similar between control and treated groups in both males (Con: 4.4 ± 0.4 ng/ml, n=5;
176 Seq: 5.1 ± 0.1, n=5; p=0.173) and females (Con: 4.9 ± 0.1 ng/ml, n=5; Seq: 4.7 ± 0.2, n=6; p=0.483).
177
These data suggest that blood insulin levels do not contribute to the hypoglycemic effect of sequoyitol 178 under these conditions. In ITT, blood glucose levels were significantly lower 15, 30, and 60 min after 179 insulin injection in both males and females (Fig. 3C ). These results suggest that sequoyitol has a potential 180 to be used as an oral diabetes medication to improve hyperglycemia and glucose intolerance. (Fig. 5D ). These data suggest that sequoyitol and its derivatives directly enhance insulin 222 sensitivity in adipocytes.
223
To determine whether sequoyitol regulates glucose uptake, 3T3-L1 adipocytes were pretreated 224 with sequoyitol for 6 or 12 h prior to insulin stimulation. Insulin stimulated glucose uptake in control 225 adipocytes as expected, and sequoyitol further increased insulin-stimulated glucose uptake by 34% and
226
81% 6 h and 12 h after pretreatments, respectively (Fig. 5E ). These data provide additional evidence 227 supporting sequoyitol as an insulin sensitizer. Prolonged sequoyitol treatments (12 h) alone also increased 228 basal glucose uptake (Fig. 5E ). In agreement, sequoyitol increased both basal and insulin-stimulated 229 glucose uptake in mouse primary adipocytes (Fig. 5F ). These data suggest that sequoyitol promotes 230 glucose uptake into adipocytes by both insulin-dependent and insulin-independent mechanisms.
231
Sequoyitol protects islet β cells against oxidative injury. similar between these two groups during the treatments (Fig. 7A) . STZ treatments progressively increased 244 blood glucose in the control group, and sequoyitol markedly attenuated STZ-induced hyperglycemia in 245 the sequoyitol-treated group (Fig. 7B ). Blood glucose levels decreased by 26% 31 days after sequoyitol 246 treatments. Sequoyitol also increased plasma insulin levels by 155% (Fig. 7C ) and significantly improved 247 glucose intolerance (Fig. 7D ). These data raise the possibility that sequoyitol may protects against β cell 248 injury.
249
Discussion
250
Herbal extracts have been reported to reduce blood glucose in animals (6, 8, 17, 22, 41) 
476
The blots were reprobed with αIRS1. Cell extracts were also immunoblotted with αpSer473 or αAkt. B:
477 Phosphorylated IRS1 and Akt were quantified by densitometry and normalized to total IRS1 and Akt DB-cAMP plus insulin (100 nM), and subjected to glucose production assays. Glucose production was 490 normalized to total hepatocyte protein levels (Con: n=4; Seq: n=4 
